샘플 요청 목록

 카트 문의
시장보고서
상품코드
1739181

이염성 백질 이영양증 치료 시장

Metachromatic Leukodystrophy Treatment
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 283 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 이염성 백질 이영양증 치료 시장은 2030년까지 33억 달러에 도달

2024년에 26억 달러로 추정되는 이염성 백질 이영양증 치료 세계 시장은 2024-2030년의 분석 기간에 CAGR 4.4%로 성장하여 2030년에는 33억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 Atidarsagene Autotemcel Drug Type는 CAGR 5.3%를 나타내고, 분석 기간 종료시에는 18억 달러에 이를 것으로 예측됩니다. DUOC-01 Drug Type 부문의 성장률은 분석 기간중 CAGR 2.8%로 추정됩니다.

미국 시장은 6억 9,790만 달러로 추정, 중국은 CAGR 8.2%를 보일 것으로 예측

미국의 이염성 백질 이영양증 치료 시장은 2024년에 6억 9,790만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 6억 9,180만 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 8.2%로 추정됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 1.7%와 3.6%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 2.6%를 보일 것으로 예측됩니다.

세계의 이염성 백질 이영양증 치료 시장 - 주요 동향과 촉진요인 정리

왜 메타색소성 백질 이영양증은 긴급하고 전문적인 치료 전략이 필요한가?

메타색소성 백질 이영양증(MLD)은 뇌와 말초신경계의 신경세포를 감싸고 있는 보호막인 미엘린의 파괴가 진행되는 희귀한 유전성 리소좀 저장 장애입니다. 아릴 설파타제 A(ARSA)라는 효소의 결핍으로 인해 올리고덴드로사이트와 슈반세포에 유독한 설파타이드가 축적됩니다. 이 질환은 심각하고 종종 치명적일 수 있으며, 유아기 말기형, 청년기형, 성인형이 있으며, 각각 증상 발현과 진행 속도가 다릅니다.

전형적인 증상으로는 운동 기능 저하, 경련, 인지 기능 저하, 발작, 언어 능력 및 운동 능력 저하 등이 있으며, 환자는 진단 후 몇년내에 완전히 의존 상태에 빠지게 됩니다. 오랜 기간 동안 치료법이 없었기 때문에 대증요법이 치료의 중심이었습니다. 그러나 유전자 치료, 효소 보충 요법, 조혈모세포 이식(HSCT)의 획기적인 발전으로 치료의 가능성이 재정의되고 있습니다. 조기 진단이 효과에 필수적이기 때문에 신생아 스크리닝, 조기 개입, 고정밀 유전자 타겟팅이 시장의 중심이 되고 있습니다.

유전자 치료와 효소 기반 접근법은 치료 패러다임을 어떻게 바꾸고 있는가?

유전자 치료의 등장은 MLD 치료에 전환점을 가져왔습니다. 가장 주목할 만한 혁신은 Orchard Therapeutics사가 개발한 MLD에 대한 최초의 승인된 체외 유전자 치료제인 Libmeldy(atidarsagene autotemcel)입니다. 이 치료법은 환자의 조혈모세포를 채취하여 렌티바이러스 벡터를 이용하여 ARSA 유전자의 기능적 복사본을 삽입하고, 골수 절제 후 컨디셔닝 후 변형된 세포를 재주입하는 방식입니다. 이 방법은 증상이 나타나기 전 초기에 시행함으로써, 특히 증상이 나타나기 전의 환자에서 질병의 진행을 멈추거나 지연시키는데 큰 가능성을 보여주고 있습니다.

효소대체요법(ERT)과 기질감소요법(SRT)도 연구되고 있습니다. 유전자 재조합 ARSA 효소를 정맥 또는 척수강 내로 투여하여 혈액뇌장벽을 통과하여 결핍된 활성을 보충하는 방법이 시험되고 있습니다. 황산화물 축적을 감소시키는 저분자 화합물이나 돌연변이 효소를 안정화시키는 샤페론 요법과 같은 보조 전략도 전임상시험에서 인기를 끌고 있습니다. 이 분야는 바이오 제약사, 희귀질환 재단, 희귀질환 치료제 개발 및 조기 승인에 우선순위를 두는 규제 당국의 협력으로 빠르게 발전하고 있습니다.

어떤 환자군, 연구기관, 지역이 치료제 개발을 주도하고 있는가?

주요 환자 집단은 소아 후기 및 소아청소년형 MLD로 진단된 어린이로, 발병이 빠르고 퇴행이 빠르기 때문에 임상적 개입에서 가장 큰 비중을 차지합니다. 이 환자들은 보통 가족력, 신경학적 평가, 희귀질환 감시 프로그램을 시행하는 국가에서 신생아 선별검사 패널을 확대하여 진단을 받게 됩니다. 성인 발병 MLD 환자들은 더 희귀하고 진행이 느린 MLD에 대한 치료 방침과 바이오마커 개발에 대한 이해를 높이기 위해 자연사 연구와 등록에 대한 참여가 증가하고 있습니다.

유럽은 여전히 MLD 치료제 개발의 주요 지역으로 영국, 독일, 이탈리아가 여러 임상센터, 공동연구, 규제당국의 파일럿 시험을 진행하고 있습니다. 북미는 임상 연구 기반을 빠르게 확장하고 있으며, NIH, 메이요 클리닉, CHOP와 같은 미국 기관들이 임상시험 및 장기 결과 데이터에 기여하고 있습니다. 아시아태평양은 진단 인프라 개발 초기 단계에 있지만, 특히 일본, 한국, 중국에서 희귀질환에 대한 자금 지원, 유전자 치료의 현지화, 신생아 유전체 연구에 대한 관심이 높아지고 있습니다.

MLD 치료제 시장의 장기적인 성장 원동력과 남은 과제는?

MLD 치료 시장의 성장은 정밀 의약품의 획기적인 발전, 희귀질환 의약품에 대한 우대 조치, 진단에 대한 인식 증가에 의해 이루어지고 있습니다. 조기 승인 제도, 소아 희귀질환 쿠폰, 희귀질환 옹호 활동 증가로 고위험, 고비용 치료법에 유리한 정책 환경이 조성되고 있습니다. 출생 시 유전자 검사를 시행하는 국가가 늘어남에 따라 무증상 MLD 환자를 식별할 수 있게 되어 조기 치료 개입을 받을 수 있는 인구가 확대될 것입니다.

이러한 발전에도 불구하고, 여전히 과제가 남아있습니다. 높은 치료 비용, 제조의 복잡성, 제한된 치료 센터가 전 세계 접근성을 저해하고 있습니다. 장기적인 유효성 확보, 안전성 모니터링, 일회성 유전자 치료에 대한 공평한 보상 체계는 시급한 과제입니다. 또한, 성인 및 진행성 환자의 경우 선택지가 제한되어 있어 신경 재생 전략과 중추신경계 지향성 효소 전달에 대한 지속적인 연구가 필요합니다.

유전자 치료가 성숙하고 개인화된 중재 프로토콜이 정교해짐에 따라 MLD 치료 환경은 크게 변화하고 있으며, 과거에는 치료가 불가능하고 치명적인 신경 퇴행성 질환으로 여겨졌던 질병에 희망을 줄 수 있는 여건이 조성되고 있습니다.

부문

약제 유형(Atidarsagene Autotemcel, DUOC-01, OTL-200, 기타 약제 유형);최종사용자(병원 최종사용자, 전문 클리닉 최종사용자, 기타 최종사용자)

조사 대상 기업 예(총 43개사)

  • Abeona Therapeutics Inc.
  • AGTC(Applied Genetic Technologies)
  • Amicus Therapeutics
  • ArmaGen Inc.
  • Asklepios BioPharmaceutical
  • Avrobio Inc.
  • BioMarin Pharmaceutical Inc.
  • bluebird bio, Inc.
  • BridgeBio Pharma
  • Denali Therapeutics Inc.
  • Freeline Therapeutics
  • Genethon
  • GlaxoSmithKline plc(GSK)
  • Homology Medicines, Inc.
  • JCR Pharmaceuticals Co., Ltd.
  • Krystal Biotech, Inc.
  • Lysogene
  • Magenta Therapeutics
  • Orchard Therapeutics plc
  • Passage Bio, Inc.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 수익원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사했습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월: 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월: 최종 관세 재설정

고객님들께는 각 국가별 최종 리셋이 발표된 후 7월에 무료 업데이트 버전을 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역과 관세의 영향 분석 :

미국 <>& 중국 <>& 멕시코 <>& 캐나다 <>&EU <>& 일본 <>& 인도 <>& 기타 176개국

업계 최고의 이코노미스트: Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황에서 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 최고 이코노미스트를 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정이 적용되어 있습니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.06.17

Global Metachromatic Leukodystrophy Treatment Market to Reach US$3.3 Billion by 2030

The global market for Metachromatic Leukodystrophy Treatment estimated at US$2.6 Billion in the year 2024, is expected to reach US$3.3 Billion by 2030, growing at a CAGR of 4.4% over the analysis period 2024-2030. Atidarsagene Autotemcel Drug Type, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the DUOC-01 Drug Type segment is estimated at 2.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$697.9 Million While China is Forecast to Grow at 8.2% CAGR

The Metachromatic Leukodystrophy Treatment market in the U.S. is estimated at US$697.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$691.8 Million by the year 2030 trailing a CAGR of 8.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR.

Global Metachromatic Leukodystrophy Treatment Market - Key Trends & Drivers Summarized

Why Does Metachromatic Leukodystrophy Demand Urgent and Specialized Therapeutic Strategies?

Metachromatic leukodystrophy (MLD) is a rare, inherited lysosomal storage disorder that results in the progressive destruction of myelin-the protective sheath surrounding nerve cells in the brain and peripheral nervous system. Caused by a deficiency in the enzyme arylsulfatase A (ARSA), MLD leads to the accumulation of sulfatides, which are toxic to oligodendrocytes and Schwann cells. The condition is severe, often fatal, and manifests in late-infantile, juvenile, or adult forms, each with varying symptom onset and progression speed.

Symptoms typically include motor regression, spasticity, cognitive decline, seizures, and loss of speech and mobility, rendering patients completely dependent within a few years of diagnosis. The absence of curative options for many years made symptom management the mainstay of care. However, breakthroughs in gene therapy, enzyme replacement, and hematopoietic stem cell transplantation (HSCT) are now redefining therapeutic potential. With early diagnosis being critical to effectiveness, the market is increasingly centered around newborn screening, early intervention, and high-precision genetic targeting.

How Are Gene Therapies and Enzyme-Based Approaches Changing the Treatment Paradigm?

The emergence of gene therapy has marked a turning point in MLD treatment. The most notable innovation is Libmeldy (atidarsagene autotemcel), the first approved ex vivo gene therapy for MLD, developed by Orchard Therapeutics. This therapy involves extracting the patient's hematopoietic stem cells, inserting a functional copy of the ARSA gene using a lentiviral vector, and re-infusing the modified cells after myeloablative conditioning. Administered early-before symptom onset-this approach has shown significant promise in halting or slowing disease progression, particularly in pre-symptomatic patients.

Enzyme replacement therapy (ERT) and substrate reduction therapy (SRT) are also being investigated. Recombinant ARSA enzymes delivered intravenously or intrathecally are being tested to overcome the blood-brain barrier and replenish deficient activity. Adjunct strategies, such as small molecules to reduce sulfatide accumulation or chaperone therapies to stabilize mutant enzymes, are gaining traction in preclinical studies. The field is rapidly advancing through collaboration between biopharma firms, rare disease foundations, and regulatory agencies prioritizing orphan drug development and accelerated approval pathways.

Which Patient Populations, Research Institutions, and Regions Are Driving Therapeutic Development?

The primary patient population comprises children diagnosed with late-infantile and juvenile forms of MLD-who represent the largest share of clinical interventions due to earlier onset and faster decline. These patients are typically diagnosed through family history, neurological assessments, or expanded newborn screening panels in countries with rare disease surveillance programs. Adult-onset MLD patients, while rarer and slower progressing, are increasingly participating in natural history studies and registries to better understand therapeutic windows and biomarker development.

Europe remains the leading region for MLD therapeutic development, with the U.K., Germany, and Italy hosting several clinical centers, research collaborations, and regulatory pilots. North America is rapidly expanding its clinical research footprint, with U.S. institutions like the NIH, Mayo Clinic, and CHOP contributing to trials and long-term outcome data. Asia-Pacific is in earlier stages of diagnostic infrastructure development but is seeing growing interest in rare disease funding, gene therapy localization, and neonatal genomics initiatives, particularly in Japan, South Korea, and China.

What Is Driving Long-Term Growth in the MLD Treatment Market and What Challenges Remain?

The growth in the MLD treatment market is driven by precision medicine breakthroughs, orphan drug incentives, and increased diagnostic awareness. Accelerated approval mechanisms, pediatric rare disease vouchers, and growing rare disease advocacy are creating a favorable policy environment for high-risk, high-cost therapies. As more countries implement genetic screening at birth, the ability to identify pre-symptomatic MLD cases will expand the eligible population for early therapeutic intervention-particularly for gene therapy candidates with time-sensitive efficacy.

Despite these advances, challenges remain. High therapy costs, manufacturing complexity, and limited treatment centers hinder global access. Ensuring long-term efficacy, safety surveillance, and equitable reimbursement mechanisms for one-time gene therapies are pressing concerns. Additionally, adult and advanced-stage patients have limited options, necessitating continued research into neuroregenerative strategies and CNS-directed enzyme delivery.

As genetic therapies mature and personalized intervention protocols are refined, the MLD treatment landscape is poised for significant transformation-offering hope for what was once considered an untreatable and devastating neurodegenerative disorder.

SCOPE OF STUDY:

The report analyzes the Metachromatic Leukodystrophy Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type, Other Drug Types); End-Use (Hospitals End-Use, Specialty Clinics End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • Abeona Therapeutics Inc.
  • AGTC (Applied Genetic Technologies)
  • Amicus Therapeutics
  • ArmaGen Inc.
  • Asklepios BioPharmaceutical
  • Avrobio Inc.
  • BioMarin Pharmaceutical Inc.
  • bluebird bio, Inc.
  • BridgeBio Pharma
  • Denali Therapeutics Inc.
  • Freeline Therapeutics
  • Genethon
  • GlaxoSmithKline plc (GSK)
  • Homology Medicines, Inc.
  • JCR Pharmaceuticals Co., Ltd.
  • Krystal Biotech, Inc.
  • Lysogene
  • Magenta Therapeutics
  • Orchard Therapeutics plc
  • Passage Bio, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Metachromatic Leukodystrophy Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Focus on Rare Disease Therapeutics Throws the Spotlight on Metachromatic Leukodystrophy Treatment
    • Advancements in Gene Therapy Platforms Drive Development of Curative MLD Interventions
    • Increased R&D Funding for Lysosomal Storage Disorders Spurs Clinical Pipeline Expansion
    • Global Regulatory Incentives and Orphan Drug Designations Strengthen Market Entry Opportunities
    • Expansion of Newborn Screening Programs Accelerates Early Diagnosis and Timely Treatment
    • Breakthroughs in Hematopoietic Stem Cell Transplantation Propel Treatment Efficacy in Pediatric Patients
    • Use of Viral Vectors and Genome Editing Tools Fuels Innovation in Ex Vivo Gene Therapies
    • Increased Collaboration Between Biopharma and Academia Supports Preclinical Study Advancements
    • Surge in Compassionate Use and Expanded Access Programs Accelerates Early Drug Adoption
    • Growing Demand for Multidisciplinary Care Models Strengthens Holistic Treatment Approaches
    • Government Grants and Rare Disease Policy Reforms Create Favorable Development Ecosystems
    • Improved Genetic Testing Technologies Enhance Patient Identification and Trial Enrollment
    • Emergence of Cell-Based and Regenerative Therapies Expands Therapeutic Modalities
    • Clinical Validation of Novel Delivery Systems for CNS-Targeted Therapies Boosts Market Confidence
    • Rising Advocacy by Rare Disease Foundations Spurs Patient Engagement and Clinical Trial Awareness
    • Growth in Pediatric Neurology Infrastructure Enhances Access to Specialized MLD Treatments
    • Limited Competition and High Unmet Need Strengthen Business Case for Innovative Drug Development
    • Rise in Biologics and Protein Replacement Research Generates Opportunities for Novel Modalities
    • Complex Manufacturing and Cost Challenges Drive Demand for Scalable Production Platforms
    • Long-Term Disease Progression Data From Ongoing Trials Supports Market Entry of Gene-Edited Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Metachromatic Leukodystrophy Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Metachromatic Leukodystrophy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Atidarsagene Autotemcel Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Atidarsagene Autotemcel Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Atidarsagene Autotemcel Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for DUOC-01 Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for DUOC-01 Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for DUOC-01 Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for OTL-200 Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for OTL-200 Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for OTL-200 Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Specialty Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Metachromatic Leukodystrophy Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Metachromatic Leukodystrophy Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Metachromatic Leukodystrophy Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Metachromatic Leukodystrophy Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제